Oxytocin antagonists as potential therapeutic agents for the treatment of preterm labour (Q36477483)

14 August 2017

1 reference

title

Oxytocin antagonists as potential therapeutic agents for the treatment of preterm labour (English)

1 reference

14 August 2017

1 reference

1 reference

Michael J Allen

1 reference

14 August 2017

David G H Livermore

series ordinal

1 reference

14 August 2017

Jacqueline E Mordaunt

series ordinal

1 reference

14 August 2017

publication date

1 January 2006

1 reference

Progress in medicinal chemistry

14 August 2017

published in

1 reference

14 August 2017

1 reference

14 August 2017

page(s)

331-373

1 reference

Preterm labour: an overview of current and emerging therapeutics.

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

The oxytocin receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

The cost of prematurity: quantification by gestational age and birth weight.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Economic consequences of preterm birth and low birthweight

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Oxytocin and the initiation of human parturition. II. Stimulation of prostaglandin production in human decidua by oxytocin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Plasma oxytocin and nocturnal uterine activity: maternal but not fetal concentrations increase progressively during late pregnancy and delivery in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Synthesis of oxytocin in amnion, chorion, and decidua may influence the timing of human parturition

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Paracrine oxytocin and estradiol demonstrate a spatial increase in human intrauterine tissues with labor.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Oxytocin receptors in the human uterus during pregnancy and parturition

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of preterm labour. The Worldwide Atosiban versus Beta-agonists Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Double-blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Maintenance treatment of preterm labor with the oxytocin antagonist atosiban. The Atosiban PTL-098 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Spontaneous contractions of myometrium from humans, non-human primate and rodents are sensitive to selective oxytocin receptor antagonism in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Effect of vasopressin blockade on blood pressure regulation during hemorrhage in conscious dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

The neurobiology of sexual function

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Lesions of the hypothalamic paraventricular nucleus disrupt the initiation of maternal behavior.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

High throughput fluorescence polarization: a homogeneous alternative to radioligand binding for cell surface receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Synthesis of 1-L-penicillamine-oxytocin, 1-D-penicillamine-oxytocin, and 1-deaminopenicillamine-oxytocin, potent inhibitors of the oxytocic response of oxytocin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

1-.beta.-Mercapto-.beta.,.beta.-pentamethylenepropionic acidoxytocin, a potent inhibitor of oxytocin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: comparisons with Atosiban

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Design of oxytocin antagonists, which are more selective than atosiban

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Improvement in potency of an oxytocin antagonist after systematic substitutions with L-tryptophan

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

1-Deaminopenicillamine,4-threonineoxytocin, a potent inhibitor of oxytocin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Design and synthesis of potent in vivo antagonists of oxytocin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Solid-phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Potent antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid),2-D- phenylalanine,4-valine]arginine-vasopressin at position 4

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Design of potent oxytocin antagonists featuring D-tryptophan at position 2

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Systematic substitution of an oxytocin antagonist with D-amino acids: unexpected high antagonistic potency of the D-Cys6-substituted analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

6-Hemi-D-cystine-oxytocin, a Diastereoisomer of the Posterior Pituitary Hormone Oxytocin1

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

A new tocolytic agent: development of an oxytocin antagonist for inhibiting uterine contractions

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Inhibition of spontaneous uterine contractions during the last trimester in pregnant baboons by an oxytocin antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Inhibition of oxytocin-induced uterine contractions by an oxytocin antagonist in the pregnant baboon

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Antagonists of oxytocin featuring replacement with modified beta-mercaptopropionic acids at position 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Analogues of a potent oxytocin antagonist with truncated C-terminus or shorter amino acid side chain of the basic amino acid at position 8

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

An exploration of the effects of L‐ and D‐tetrahydroisoquinoline‐3‐carboxylic acid substitutions at positions 2,3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Noncompetitive nature of oxytocin antagonists with general structure Mpa(1)Xxx(2)Sar(7)Arg(8).

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

The influence of steric interactions on the conformation and biology of oxytocin. Synthesis and analysis of penicillamine(6)-oxytocin and penicillamine(6)-5-tert-butylproline(7)-oxytocin analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Crystal structure analysis of deamino-oxytocin: conformational flexibility and receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Structure-activity studies of a novel bicyclic oxytocin antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Conformationally restricted analogs of oxytocin; stabilization of inhibitory conformation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

A structurally unique, potent, and selective oxytocin antagonist derived from Streptomyces silvensis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Receptor ligands which bind the oxytocin receptor with selectivity and high affinity. Chemical modification of a Streptomyces silvensis derived cyclic hexapeptide

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Inhibitory effect of O-alkylated analogues of oxytocin and vasopressin on human and rat myometrial activity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Synthetic antagonists of the myometrial response to vasopressin and oxytocin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

The synthesis of a new class of oxytocin antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Orally active, nonpeptide oxytocin antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Nanomolar-affinity, non-peptide oxytocin receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

1 reference

7 January 2021

The role of drug metabolism in drug discovery: a case study in the selection of an oxytocin receptor antagonist for development

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Key amino acids of vasopressin V1a receptor responsible for the species difference in the affinity of OPC-21268

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potency

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

A nonpeptide oxytocin receptor antagonist radioligand highly selective for human receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Identification of potent and selective oxytocin antagonists. Part 1: indole and benzofuran derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Identification of potent and selective oxytocin antagonists. Part 2: further investigation of benzofuran derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Identification of a potent and selective oxytocin antagonist, from screening a fully encoded differential release combinatorial chemical library

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Structure-activity relationship investigations of a potent and selective benzodiazepine oxytocin antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

2,5-Diketopiperazines as potent and selective oxytocin antagonists 1: Identification, stereochemistry and initial SAR.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

SSR126768A (4-chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, hydrochloride): a new selective and orally active oxytocin receptor antagonist for the prevention of p

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 2-phenyl-4'-(2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-1-carbonyl) benzanilide derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

The design, synthesis and physical chemical properties of novel human vasopressin V2-receptor antagonists optimized for parenteral delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Pharmacologic characterization of the oxytocin receptor in human uterine smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Non-peptide oxytocin agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Identification of the binding sites of the SR49059 nonpeptide antagonist into the V1a vasopressin receptor using sulfydryl-reactive ligands and cysteine mutants as chemical sensors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Docking ligands to vasopressin and oxytocin receptors via genetic algorithm

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Molecular modeling of the neurohypophyseal receptor/atosiban complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Characterization of the human oxytocin receptor ligand binding site

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Critical role of a subdomain of the N-terminus of the V1a vasopressin receptor for binding agonists but not antagonists; functional rescue by the oxytocin receptor N-terminus.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Identification of an extracellular segment of the oxytocin receptor providing agonist-specific binding epitopes.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Agonist binding to peptide hormone receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

Molecular pharmacology of human vasopressin receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944407-0

7 January 2021

10.1016/S0079-6468(05)44407-0

Identifiers

DOI

1 reference

14 August 2017

1 reference